Aerosolized Amiloride for the Treatment of Lung Disease in Cystic Fibrosis

Richard L. Gallo, Jack Henkin, Michael R. Knowles, Nina L. Church, William E. Waltner, James R. Yankaskas, Peter Gilligan, Malcolm King, Lloyd J. Edwards, Ronald W. Helms, Richard C. Boucher

Research output: Contribution to journalLetter

6 Scopus citations

Abstract

To the Editor: The April 26 issue of the Journal presented encouraging results by Knowles et al. regarding the beneficial effects of aerosolized amiloride in the treatment of cystic fibrosis.1 The introduction and discussion sections of this article described the function of amiloride as an inhibitor of sodium transport in the airway epithelium, and the authors suggested that the beneficial effects observed were exerted “at least in part by increasing the clearance of secretions.” Although the results of this investigation were promising in terms of the improvement in the decline of forced vital capacity in patients with cystic fibrosis, this.

Original languageEnglish (US)
Pages (from-to)996-998
Number of pages3
JournalNew England Journal of Medicine
Volume323
Issue number14
DOIs
StatePublished - Oct 4 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Aerosolized Amiloride for the Treatment of Lung Disease in Cystic Fibrosis'. Together they form a unique fingerprint.

  • Cite this

    Gallo, R. L., Henkin, J., Knowles, M. R., Church, N. L., Waltner, W. E., Yankaskas, J. R., Gilligan, P., King, M., Edwards, L. J., Helms, R. W., & Boucher, R. C. (1990). Aerosolized Amiloride for the Treatment of Lung Disease in Cystic Fibrosis. New England Journal of Medicine, 323(14), 996-998. https://doi.org/10.1056/NEJM199010043231416